XTRA:FME

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Fresenius Medical Care KGaA

Executive Summary

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally.


Snowflake Analysis

Established dividend payer and good value.


Similar Companies

Share Price & News

How has Fresenius Medical Care KGaA's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: FME's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.9%

FME

0.5%

DE Healthcare

3.2%

DE Market


1 Year Return

15.8%

FME

2.4%

DE Healthcare

0.01%

DE Market

Return vs Industry: FME exceeded the German Healthcare industry which returned 2.4% over the past year.

Return vs Market: FME exceeded the German Market which returned 0% over the past year.


Shareholder returns

FMEIndustryMarket
7 Day0.9%0.5%3.2%
30 Day5.5%5.9%4.7%
90 Day9.1%4.3%-0.9%
1 Year15.8%15.8%2.8%2.4%1.7%0.01%
3 Year-10.1%-12.6%-27.1%-29.5%-6.8%-14.0%
5 Year3.6%-1.5%-10.0%-14.2%3.9%-9.5%

Price Volatility Vs. Market

How volatile is Fresenius Medical Care KGaA's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Fresenius Medical Care KGaA undervalued compared to its fair value and its price relative to the market?

45.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: FME (€75.6) is trading below our estimate of fair value (€139.5)

Significantly Below Fair Value: FME is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: FME is good value based on its PE Ratio (18.7x) compared to the Healthcare industry average (26.2x).

PE vs Market: FME is good value based on its PE Ratio (18.7x) compared to the German market (18.9x).


Price to Earnings Growth Ratio

PEG Ratio: FME is poor value based on its PEG Ratio (1.8x)


Price to Book Ratio

PB vs Industry: FME is overvalued based on its PB Ratio (1.8x) compared to the DE Healthcare industry average (1.4x).


Next Steps

Future Growth

How is Fresenius Medical Care KGaA forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?

10.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: FME's forecast earnings growth (10.4% per year) is above the savings rate (0.2%).

Earnings vs Market: FME's earnings (10.4% per year) are forecast to grow slower than the German market (21.6% per year).

High Growth Earnings: FME's earnings are forecast to grow, but not significantly.

Revenue vs Market: FME's revenue (5.7% per year) is forecast to grow slower than the German market (5.7% per year).

High Growth Revenue: FME's revenue (5.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: FME's Return on Equity is forecast to be low in 3 years time (11.4%).


Next Steps

Past Performance

How has Fresenius Medical Care KGaA performed over the past 5 years?

10.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: FME has high quality earnings.

Growing Profit Margin: FME's current net profit margins (6.8%) are lower than last year (11.8%).


Past Earnings Growth Analysis

Earnings Trend: FME's earnings have grown by 10.7% per year over the past 5 years.

Accelerating Growth: FME's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: FME had negative earnings growth (-38.4%) over the past year, making it difficult to compare to the Healthcare industry average (6.1%).


Return on Equity

High ROE: FME's Return on Equity (11%) is considered low.


Next Steps

Financial Health

How is Fresenius Medical Care KGaA's financial position?


Financial Position Analysis

Short Term Liabilities: FME's short term assets (€7.9B) do not cover its short term liabilities (€8.6B).

Long Term Liabilities: FME's short term assets (€7.9B) do not cover its long term liabilities (€12.2B).


Debt to Equity History and Analysis

Debt Level: FME's debt to equity ratio (73.8%) is considered high.

Reducing Debt: FME's debt to equity ratio has reduced from 82.6% to 73.8% over the past 5 years.

Debt Coverage: FME's debt is well covered by operating cash flow (31.4%).

Interest Coverage: FME's interest payments on its debt are well covered by EBIT (5.2x coverage).


Balance Sheet


Next Steps

Dividend

What is Fresenius Medical Care KGaA's current dividend yield, its reliability and sustainability?

1.59%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: FME's dividend (1.59%) is higher than the bottom 25% of dividend payers in the German market (1.29%).

High Dividend: FME's dividend (1.59%) is low compared to the top 25% of dividend payers in the German market (3.86%).


Stability and Growth of Payments

Stable Dividend: FME's dividends per share have been stable in the past 10 years.

Growing Dividend: FME's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (29.8%), FME's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: FME's dividends in 3 years are forecast to be well covered by earnings (25.8% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.6yrs

Average management tenure


CEO

Rice Powell (64yo)

7.33yrs

Tenure

€6,867,000

Compensation

Mr. Robert Maurice Powell, Jr., also known as Rice, has been the Chief Executive Officer and Chairman of Management at Fresenius Medical Care Management AG, General Partner of Fresenius Medical Care AG & C ...


CEO Compensation Analysis

Compensation vs Market: Rice's total compensation ($USD7.63M) is above average for companies of similar size in the German market ($USD5.08M).

Compensation vs Earnings: Rice's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Robert Powell
Chairman of the Management Board & CEO of Fresenius Medical Care Mgmt AG7.33yrs€6.87mno data
Helen Giza
CFO & Member of Management Board of Fresenius Medical Care Mgmt AG0.50yr€2.13mno data
Kent Wanzek
CEO of Global Mfg10.33yrs€3.19mno data
Olaf Schermeier
CEO of Global R&D and Member of the Management Board - Fresenius Medical Care Mgmt AG7.17yrs€2.72mno data
Harry de Wit
CEO of APAC & Member of Management Board - Fresenius Medical Care Mgmt AG4.08yrs€4.59mno data
William Valle
CEO of North America & Member of Management Board at Fresenius Medical Care Mgmt AG3.17yrs€3.67mno data
Katarzyna Mazur-Hofsäß
CEO for EMEA & Member of Management Board - Fresenius Medical Care Mgmt AG1.67yrs€3.13mno data
Rachel Empey
Member of Supervisory Board - FMC Management AGno data€79.00kno data
Franklin Maddux
Global Chief Medical Officer & Member of Management board of Fresenius Medical Care Mgmt AG0.33yrno datano data
Dominik Heger
Executive VP and Head of Investor Relationsno datano datano data

3.6yrs

Average Tenure

57yo

Average Age

Experienced Management: FME's management team is considered experienced (3.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Benjamin Lipps
Honorary Chairman of Supervisory Board3.83yrsno datano data
Rolf Classon
Independent Vice Chairman of Supervisory Board1.5yrs€285.00kno data
Dieter Schenk
Chairman of Supervisory Board2yrs€296.00kno data
William Johnston
Independent Member of Supervisory Board14yrs€245.00kno data
Gregor Zünd
Independent Member of Supervisory Board1.58yrs€79.00kno data
Pascale Witz
Independent Member of Supervisory Board4yrs€139.00kno data
Dorothea Wenzel
Independent Member of Supervisory Board1yr€45.00kno data

2.0yrs

Average Tenure

66yo

Average Age

Experienced Board: FME's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Fresenius Medical Care AG & Co. KGaA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Fresenius Medical Care AG & Co. KGaA
  • Ticker: FME
  • Exchange: XTRA
  • Founded: 1996
  • Industry: Health Care Services
  • Sector: Healthcare
  • Market Cap: €22.124b
  • Shares outstanding: 292.65m
  • Website: https://www.freseniusmedicalcare.com

Number of Employees


Location

  • Fresenius Medical Care AG & Co. KGaA
  • Else-Kroner Strasse 1
  • Bad Homburg
  • Hessen
  • 61352
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FMSNYSE (New York Stock Exchange)SPONSORED ADRUSUSDSep 1996
FMEADB (Deutsche Boerse AG)SPONSORED ADRDEEURSep 1996
FMCQ.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDOct 1996
FMEDB (Deutsche Boerse AG)YesOrdinary SharesDEEUROct 1996
0H9XLSE (London Stock Exchange)YesOrdinary SharesGBEUROct 1996
FMEXTRA (XETRA Trading Platform)YesOrdinary SharesDEEUROct 1996
FMEDBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBEUROct 1996
FMEWBAG (Wiener Boerse AG)YesOrdinary SharesATEUROct 1996
FME NBMV (Bolsa Mexicana de Valores)YesOrdinary SharesMXMXNOct 1996
FMESWX (SIX Swiss Exchange)YesOrdinary SharesCHCHFOct 1996
FMEBIT (Borsa Italiana)YesOrdinary SharesITEUROct 1996

Biography

Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides pharmacy services, vascular, cardiovascular, endovascular specialty, hospitalist, emergency, intensivist, medical cost management, ambulatory surgery center, health plan, urgent care, physician nephrology and cardiology, and ambulant treatment services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2019, it operated 3,994 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/30 22:33
End of Day Share Price2020/05/29 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.